CIENCIASMEDICASNEWS

Melanoma Clues Every Primary Care Physician Should Know

https://www.medscape.com/viewarticle/melanoma-clues-every-primary-care-physician-should-know-2026a1000p2p?src=

Oral Cancer Screening in Rural Hungary Detects Lesions but Follow-Up Remains Low Edited by Gargi Mukherjee

https://www.medscape.com/viewarticle/oral-cancer-screening-rural-hungary-detects-lesions-follow-2026a1000pe4?src= Mobile screening units in rural Hungary identified oral mucosal lesions in 1 in 20 adults screened between June 2021 and March 2023; however, only 3.8% of those who screened positive attended specialist follow-up, resulting in six confirmed malignant neoplasms

Childhood Cancer Incidence Is Associated With Socioeconomic Status Evra Taylor

https://www.medscape.com/viewarticle/childhood-cancer-incidence-associated-socioeconomic-status-2026a1000pgu?src= The incidence of childhood cancer is as much as 15% higher in the least marginalized neighborhoods than in the most marginalized areas, a study suggests.

EMA Recommends New Hematology and Supportive Care Drugs Edited by Zeel Mehta

https://www.medscape.com/viewarticle/ema-recommends-new-hematology-and-neutropenia-drugs-2026a1000peb?src= Two established hematology-oncology treatments, a generic ruxolitinib and a pegfilgrastim biosimilar, moved closer to EU approval after the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued positive opinions for both at its July meeting.

New European Hodgkin Lymphoma Guidelines Update Management Dr Elisa Riera

https://www.medscape.com/viewarticle/new-european-hodgkin-lymphoma-guidelines-update-management-2026a1000pdv?src= The European Hematology Association has published its 2026 clinical practice guidelines for the diagnosis, treatment, and follow-up of Hodgkin lymphoma. This document standardizes the management of a malignant neoplasm of lymphoid origin that primarily affects young adults, with a second peak in incidence among people older than 55 years.

ACE Inhibitors vs ARBs: Long-Term Cancer Risk Varies July 28, 2026

https://www.medscape.com/viewarticle/ace-inhibitors-vs-arbs-long-term-cancer-risk-varies-2026a1000pij?src= Patients treated exclusively with angiotensin-converting enzyme inhibitors (ACEIs) had lower overall cancer incidence than those treated exclusively with angiotensin receptor blockers (ARBs) over 23 years of follow-up. ACEI therapy was linked to lower odds for breast, prostate, melanoma, non-Hodgkin lymphoma, kidney, and colorectal cancers, but higher odds for lung, bladder, and pancreatic cancers.